-
Admin
GI-targeted oral JAK inhibitor shows promise in Phase I Study: TD-1473
Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial…
-
Admin
Genetically modified T-cell therapy granted enhanced EMA regulatory pathway: KTE-C19
Kite Pharma granted access to PRIME regulatory support for KTE-C19…
-
Admin
Pipeline biosimilar for asthma meets primary endpoint in P2/3 study
In Brief Biosimilar News reports that Sorrento’s experimental anti-IgE biosimilar,…
-
Admin
Medication reminders via “smart” bottle cap and app – utilization in clinical research?
Smart Bottle?Pharmacy Delivery Service According to a new report in…
-
Admin
Patients who participate in clinical trials – insights into their thinking and desires
Interviews by Marie Lux give great insights on patients: How…
Latest Posts
Categories
- Best Practices
- Change Management
- Clinical
- Clinical Trials
- Collaboration
- Communication
- Complexity
- Governance
- International Clinical Trials Day
- Leadership
- Marketing
- Medical Education
- MSL
- Patient-centered
- Pharma News
- PMOs
- Portfolio Management
- Program Management
- Project Management
- Project Management Salaries
- Project/Program/Portfolio Management
- Recruiting
- Salaries
- Uncategorized
Tags
3SixtyPharma Alzheimer's Anti-IgE anti-inflammatory anti-TNF anti-TNF-? B-cell Biosimilar clinical clinical research CNS Communication CT-P13 DEMENTIA FDA gastrointestinal genome GI Inflammation Inflectra infliximab interchangeability investigational JAK inhibitor KTE-C19 Lymphoma oncology patients Pharma Portfolio Management Program Management Project Management rare disease remote Remsima rheumatoid arthritis spondyloarthritis switching Theravance Biopharma virtual w webinar White House White House Office of Management and Budget White House OMB